Biomedical subjects

A Sardella

Publications and source records attributed to A Sardella.

40 records · Page 3Linked to original sources

PubMed1980

[Modifications in the feeding behavior of the rat, induced by antimitotic drugs: effects of hydroxyurea].

The effects of Hydroxyurea treatment on food intake and on the self-selection between a protein free diet and a complete one are different from those observed during Cyclophosphamide and Mustine Hydrochloride treatment and appear to be similar to those observed during Methotrexate treatment; these may be referred exclusively to a toxic action of the drug on the liver and on the mucous membranes of digestive apparatus. The urea, a product of Hydroxyurea metabolism, does not seem to induce modifications on food intake both as to the quantitative and qualitative aspect.

Animals↗

PubMedDate not supplied

Protective effects of BAY U 3405, a thromboxane A2 receptor antagonist, in endotoxin shock.

The present study was designed to investigate the effects of BAY U 3405, a new thromboxane A2 (TxA2) receptor antagonist, in endotoxin shock. Endotoxin shock (ES) was induced in male rats by an i.v. injection of Salmonella enteritidis lipopolysaccharide (LPS; 20 mg kg-1). LPS administration caused animal death (survival = 0%, 48 h after endotoxin challenge), systemic hypotension, depressed phagocytosis and increased blood levels of TNF-alpha, TxB2 and 6-keto-PGF1 alpha, reduced white blood cell (WBC) count (ES = 5.9 +/- 1 x 10(3) mm-3; CTRL = 13.4 +/- 5 x 10(3) mm-3) and enhanced myeloperoxidase (MPO) activity, studied as a quantitative means for assessing leukocyte accumulation, in the ileum (ES = 0.24 +/- 0.7 U g-1 fresh tissue; CTRL = 0.13 +/- 0.04 U g-1 fresh tissue), in the heart (ES = 0.41 +/- 0.1 U g-1 fresh tissue; CTRL = 0.16 +/- 0.08 U g-1 fresh tissue) and in the lung (ES = 0.68 +/- 0.11 U g-1 fresh tissue; CTRL = 0.19 +/- 0.05 U g-1 fresh tissue). Furthermore, endotoxin administration produced characteristic damage of the gastric mucosa consisting of haemmorrhagic infiltrates. BAY U 3405 (30 mg kg-1 i.v., 30 min before endotoxin challenge) increased survival rate (45% survival rate 48 h after endotoxin challenge), reduced hypotension, decreased TNF-alpha levels in serum, enhanced phagocytic activity (ES = 25.6 +/- 1.9%, BAY U 3405 = 45.9 +/- 0.4%, P < 0.001) and lowered MPO activity in the ileum (0.14 +/- 0.05 U g-1 fresh tissue), in the heart (0.18 +/- 0.08 U g-1 fresh tissue) and in the lung (0.44 +/- 0.09 U g-1 fresh tissue). Finally, the gastric alterations were significantly reduced in rats pretreated with BAY U 3405. These data suggest that this thromboxane receptor antagonist might be a useful drug in shock conditions.

Analysis of Variance↗

PubMedDate not supplied

[BMS: S for syndrome or S for symptom? A reappraisal of the burning mouth syndrome].

In this article, some nosological and ethiopathogenetic aspects of Burning Mouth Syndrome (BMS) are critically evaluated. Despite the number of papers frequently published on this subject, there is still no universally accepted definition of this disorder. Therefore, a premise on which to base an experimental approach is missing. This also leads to a lack of parameters for comparing the clinical-experimental experiences reported in various studies in this field. Moreover, it makes it rather easy to verify the absence of definitive scientific proof as well. Such proof would allow researches to consider the etiological aspects presented in the literature thus far as certain. Due to this lack of certainty, it might be prudent to introduce the concept of idiopathic (or essential) BMS to indicate a burning sensation in the oral cavity when the etiology is unknown and not correlated to noticeable local or systemic alterations. This would be true BMS. In other words, many local and/or systemic anomalies could lead to a burning type of symptomatology localised in the oral cavity but this does not constitute a sufficient requisite to indicate a diagnosis of BMS, according to the authors.

Burning Mouth Syndrome↗

PubMedDate not supplied

Osteonecrosis of the jaws in patients treated with bisphosphonates. Review of the literature and the Milan experience.

AIM: A series of 5 patients with osteonecrosis of the jaws possibly related to the use of bisphosphonates is presented. A brief review of the literature is also proposed. METHODS: A retrospective review of patients who received bisphosphonates and who developed osteonecrosis of the jaws following minor oral surgery was performed. RESULTS: In all 5 patients, a tooth extraction preceded the onset of osteonecrosis of the mandible. Patients were on chronic use of intravenous bisphosphonates. The presenting lesions was a nonhealing extraction socket and an exposed jawbone. Biopsy of the bone lesions showed no evidence of metastatic involvement. Antibiotic therapy, conservative debridement and, in some cases, bone sequestrectomy were performed. CONCLUSIONS: Osteonecrosis of the jaws appears to have a relationship with the use of bisphosphonates. It is important that medical oncologists and dentists become aware of this possible complication in order to perform minor oral surgery prior to starting bisphosphonates treatment.

Aged↗